CHARACTERIZATION OF THE INVIVO BEHAVIOR OF A CONTROLLED-RELEASE FORMULATION OF LEVODOPA (SINEMET CR)

被引:42
|
作者
WILDING, IR
HARDY, JG
DAVIS, SS
MELIA, CD
EVANS, DF
SHORT, AH
SPARROW, RA
YEH, KC
机构
[1] UNIV NOTTINGHAM,SCH PHARM,DEPT PHARMACEUT SCI,NOTTINGHAM NG7 2RD,ENGLAND
[2] QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND
[3] MERCK SHARP & DOHME LTD,W POINT,PA 19486
关键词
SINEMET CR; LEVODOPA; CARBIDOPA; GAMMA-SCINTIGRAPHY; GASTROINTESTINAL TRANSIT; ABSORPTION;
D O I
10.1097/00002826-199108000-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The gastrointestinal transit and systemic absorption of Sinement CR(50-200) controlled-release tablets and standard Sinemet (25-100) immediate-release (IR) tablets have been studied in fasted and fed healthy human subjects. Both formulations were labelled with a gamma-emitting radionuclide and their gastric emptying, colon arrival and in vivo disintegration profiles monitored using gamma scintigraphy. The IR dosage forms were found to disperse soon after administration and to empty rapidly from both fasted and fed stomachs. Erosion of the CR system was independent of food or stomach pH. The CR tablet was observed to disintegrate fully in the gastrointestinal (GI) tract, resulting in complete release of levodopa over a 3-4 h time period. Considerable intersubject variation was found to exist for levodopa absorption. Absorption was more protracted with Sinemet CR than with standard Sinemet, due to the controlled release characteristics of the tablet matrix. There was no rapid initial absorption phase and instead, a gradual build-up in the absorption profile occurred.
引用
收藏
页码:305 / 321
页数:17
相关论文
共 50 条
  • [11] CONTROLLED-RELEASE LEVODOPA
    BLUMENTHAL, HJ
    NEUROLOGY, 1993, 43 (12) : 2728 - 2729
  • [12] CONTROLLED-RELEASE LEVODOPA CARBIDOPA .3. SINEMET CR5 TREATMENT OF RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE
    CEDARBAUM, JM
    HOEY, M
    KUTT, H
    MCDOWELL, FH
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (02) : 168 - 173
  • [13] CONTROLLED-RELEASE LEVODOPA CARBIDOPA .1. SINEMET CR3 TREATMENT OF RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE
    CEDARBAUM, JM
    BRECK, L
    KUTT, H
    MCDOWELL, FH
    NEUROLOGY, 1987, 37 (02) : 233 - 241
  • [14] CONTROLLED-RELEASE LEVODOPA CARBIDOPA .2. SINEMET CR4 TREATMENT OF RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE
    CEDARBAUM, JM
    BRECK, L
    KUTT, H
    MCDOWELL, FH
    NEUROLOGY, 1987, 37 (10) : 1607 - 1612
  • [15] CONTROLLED-RELEASE - LEVODOPA - REPLY
    PAHWA, R
    KOLLER, WC
    NEUROLOGY, 1993, 43 (12) : 2729 - 2729
  • [16] PHARMACODYNAMIC MODELING OF CONCENTRATION-EFFECT RELATIONSHIPS AFTER CONTROLLED-RELEASE CARBIDOPA LEVODOPA (SINEMET-CR4) IN PARKINSONS-DISEASE
    NELSON, MV
    BERCHOU, RC
    LEWITT, PA
    KARETI, D
    GALLOWAY, MP
    NEUROLOGY, 1990, 40 (01) : 70 - 74
  • [17] CONTROLLED-RELEASE CARBIDOPA LEVODOPA COMBINATION
    GOETZ, CG
    TANNER, CM
    CARROLL, VS
    SHANNON, K
    KLAWANS, HL
    NEUROLOGY, 1986, 36 (04) : 217 - 217
  • [18] LEVODOPA CONTROLLED-RELEASE PREPARATIONS - DISCUSSION
    SAGAR
    CHASE, TN
    MEYRIGNAC
    BIRNBERGER
    LEWITT, PA
    QUINN
    OERTEL, WH
    STOCCHI
    POEWE, W
    BLANCHETTE
    LACHENMEYER
    MCMAHON
    NEUROLOGY, 1993, 43 (12) : 38 - 40
  • [19] CONTROLLED-RELEASE LEVODOPA/CARBIDOPA-25/100 (SINEMET CR-25/100) - PHARMACOKINETICS AND CLINICAL EFFICACY IN UNTREATED PARKINSONIAN-PATIENTS
    HAMMERSTAD, JP
    WOODWARD, WR
    NUTT, JG
    GANCHER, ST
    BLOCK, GA
    CYHAN, G
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 (05) : 429 - 434